Pull Up Tonix Pharmaceuticals (Nasdaq: TNXP) and Get it on Your Watchlist Right Now

There's No Time to Waste - Get Ready Now!

Pull Up Tonix Pharmaceuticals (Nasdaq: TNXP) and Get it on Your  Watchlist Right Now! Tonix Pharmaceuticals (Nasdaq: TNXP) Comes Back with Several  Potential Catalysts Including: Urgent Global Health Focus: With The WHO Declaring MPX A Global Health Emergency Due To A Severe Strain In Africa, Tonix Pharmaceuticals (Nasdaq: TNXP) Is Leading The Development Of Critical Vax Solutions, Positioning The Company Prominently In The Healthcare Sector. Limited Float: With Fewer Than 23M Shares Available, Tonix Pharmaceuticals (Nasdaq: TNXP) Could Experience Significant Movements If Demand Rises, Making It One To Watch Closely. Potential Technical Reversal: Technical Indicators, Including RSI Levels Pointing To A Severely Oversold State, Suggest Tonix Pharmaceuticals (Nasdaq: TNXP) May Be Nearing A Pivotal Trend Reversal, Warranting Close Attention. Cutting-Edge Vax Development: Tonix Pharmaceuticals (Nasdaq: TNXP) Is Developing TNX-801, a Vax Candidate Rooted In Edward Jenner’s Small-px Vax, Now Adapted To Combat MPX. Innovative Immunology Portfolio: Tonix Is Advancing Immunology With Products Like TNX-1500, A Monoclonal Antibody Targeting CD40-Ligand For Preventing Organ Transplant Rejection And Treating Autoimmune Diseases. Strong Government Partnerships: Tonix Pharmaceuticals (Nasdaq: TNXP) Secured A $34M Contract With The U.S. Department Of Defense, Reinforcing Its Role In Enhancing Medical Readiness Against Biological Threats. CNS Disorder Focus: Tonix Pharmaceuticals (Nasdaq: TNXP) Is Advancing In CNS Disorder Treatment, With TNX-102 SL For Fibromyalgia Management Approaching FDA Approval, Supported By FDA Fast Track Designation. August 27, 2024 Dear Reader, Just yesterday, Tonix Pharmaceuticals (NASDAQ: TNXP) and Bilthoven Biologicals have announced a groundbreaking collaboration to accelerate the development of TNX-801, Tonix’s MPX vax candidate.  The urgency of this collaboration comes as the World Health Organization (WHO) has declared the spread of MPX in multiple African countries a public health emergency of international concern for the second time in two years.  The new Clade 1 strain of MPX, with a mortality rate of up to 10%, presents a significant global threat, underscoring the need for a widely available and affordable single-dose vax. See the full story here. As the World Health Organization reinstates (“MPX”) as a global health emergency due to a severe strain spreading in Africa, the need for effective vaxx solutions has never been more urgent.  Immediately start your research on Tonix Pharmaceuticals (Nasdaq: TNXP). But you'll need to hurry because Tonix Pharmaceuticals (Nasdaq: TNXP) closed around $.374 pm yesterday, and has fewer than 23 Mln shares available in its float.  This limited float means the potential for significant price movements could occur if demand shifts.  As a nano-cap company with a market cap under $2M, Tonix Pharmaceuticals (Nasdaq: TNXP) could be positioned for a higher growth potential.  Tonix Pharmaceuticals (Nasdaq: TNXP)’s technical indicators reveal that it could be entering a severely oversold state.  With RSI levels at 9-Day: 34.06%, 14-Day: 28.57%, and 20-Day: 26.23, there are strong indications of a potential trend reversal. In fact, Tonix Pharmaceuticals (Nasdaq: TNXP) moved approximately 17% in one day after coming off its 52-week low of $.3259 on 8/21 and reached $.384 the very next day. Adding to this, Alliance Global Partners analyst James Molloy recently(on 8/22) raised the firm’s target on Tonix Pharmaceuticals (Nasdaq: TNXP) to $11 from $6, maintaining a bullish rating on the company. This upgrade reflects growing confidence in the company's future performance and potential market recovery. Keep reading to see why Tonix Pharmaceuticals (Nasdaq: TNXP) needs to be at the top of your watchlist. The WHO also is asking companies and organizations to bring in their vax’s, inviting developers of MPX vax’s to submit an Expression of Interest for Emergency Use Listing (EUL). Amid this backdrop, Tonix Pharmaceuticals (Nasdaq: TNXP) is developing a vaxx candidate, called TNX-801, that could play a role in combating this escalating global health crisis.  Tonix Pharmaceuticals (Nasdaq: TNXP) has successfully completed non-human primate studies showing protection from challenge with lethal doses of the Clade 1 MPX virus that is driving the new epidemic. Tonix Pharmaceuticals (Nasdaq: TNXP) is a fully-integrated biopharmaceutical company dedicated to developing, licensing, and commercializing therapeutics to treat and prevent human diseases while alleviating suffering.  The company's extensive portfolio spans various medical fields, with a particular focus on central nervous system (CNS) disorders, immunology, rare diseases, and infectious diseases.  Tonix Pharmaceuticals (Nasdaq: TNXP)’s innovative approach, state-of-the-art facilities, and strategic partnerships have positioned it as a key player in the biopharmaceutical industry, driving significant advancements in medicine. TNX-801: A Modern Twist on a Centuries-Old Vax A recent and noteworthy development is Tonix's work on TNX-801, a vax candidate designed to combat the re-emerging threat of MPX.  This initiative gained urgency as the World Health Organization (WHO) declared MPX a public health emergency of international concern on August 14, following a surge in cases in the Democratic Republic of the Congo and other African countries. TNX-801 is rooted in the science of Edward Jenner’s small-px vax, which successfully eradicated the small-px virus. This vax candidate has shown promising results in non-human primate studies, demonstrating protection from lethal doses of the Clade 1 MPX virus.  The WHO has called on vax manufacturers to step up efforts to curb the spread of the new, more deadly strain of the virus, and TNX-801 could be a key player in this global health crisis. The Science Behind TNX-801 Unlike m-R-N-A vax’s that primarily elicit an antibody response, requiring frequent booster shots, TNX-801 is designed to trigger a robust T-cell response.  T-cells have the ability to recognize and remember internal parts of viral proteins, providing long-term immunity.  This approach could potentially eliminate the need for repeated boosters, offering durable protection against MPX and other infectious diseases. Tonix is moving quickly to manufacture TNX-801 for Phase 1 human trials, with the potential to make a significant impact in the fight against MPX and other global health threats.  The vax platform on which TNX-801 is based also has broader applications, including a version designed to protect against the virus that caused the last global pandemic.   This platform has been recognized by the U.S. National Institutes of Health (NIH) through its selection for Project NextGen, aimed at developing next-generation vax’s. A Strategic Partnership with the U.S. Department of Defense In a major development, Tonix recently secured a contract with the U.S. Department of Defense (DoD), through its Defense Threat Reduction Agency (DTRA), for up to $34M over five years.  This Other Transaction Agreement (OTA) focuses on the development of TNX-4200, a small molecule broad-spectrum antiviral agent targeting CD45.  This groundbreaking initiative aims to enhance the medical readiness of military personnel exposed to biological threats, reflecting Tonix's commitment to addressing critical global health challenges. Tonix's infectious disease research facility in Frederick, MD, plays a central role in this effort.  This state-of-the-art facility is complemented by their Good Manufacturing Practice (GMP)-capable advanced manufacturing facility in Dartmouth, MA.   The Dartmouth facility was specifically designed to manufacture TNX-801 and can be swiftly reactivated in response to national or international emergencies, underscoring Tonix's preparedness for rapid deployment of life-saving therapeutics. Focus on Central Nervous System Disorders Tonix Pharmaceuticals (Nasdaq: TNXP)’s development portfolio is heavily centered on CNS disorders, an area of high unmet medical need.  A key milestone in this domain is the anticipated submission of a New Application (NDA) to the FDA in the second half of 2024 for TNX-102 SL, a product candidate for fibromyalgia management.  TNX-102 SL has already completed two statistically significant Phase 3 studies and has been granted Fast Track designation by the FDA, highlighting its potential to meet the needs of patients suffering from this debilitating condition. Beyond fibromyalgia, TNX-102 SL is also being developed to treat acute stress reactions, expanding its potential applications in CNS disorders.   Tonix Pharmaceuticals (Nasdaq: TNXP)’s CNS portfolio further includes TNX-1300 (co-cai-ne esterase), a biologic designed to treat co-cai-ne intoxication, which has been recognized with Breakthrough Therapy designation by the FDA. Advancements in Immunology and Infectious Diseases Tonix’s immunology development portfolio is another critical component of their research, focusing on biologics aimed at addressing organ transplant rejection, autoimmunity, and cancer.  Among the most promising candidates is TNX-1500, a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154).  TNX-1500 is currently under development for the prevention of allograft rejection and the treatment of autoimmune diseases, representing a significant advancement in immunological therapies. In addition to CNS and immunology, Tonix Pharmaceuticals (Nasdaq: TNXP) has been at the forefront of developing therapeutics for rare and infectious diseases.  The company’s commercial subsidiary, Tonix Medicines, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg, both approved for the treatment of acute migraine in adults.  These products demonstrate Tonix's commitment to addressing a broad spectrum of medical conditions. Addressing Future Pandemics As the world faces an increasing number of infectious disease threats, Tonix Pharmaceuticals is not only addressing the current MPX crisis but is also laying the groundwork for a future where pandemics can be more effectively contained.  The company’s innovative vax platforms and broad-spectrum antiviral agents reflect a deep commitment to global health, positioning Tonix as a leader in biopharmaceutical innovation. Tonix Pharmaceuticals (Nasdaq: TNXP) is making significant strides in the biopharmaceutical industry, with a focus on developing therapies that address critical health challenges across CNS disorders, immunology, rare diseases, and infectious diseases.  Their recent contract with the U.S. Department of Defense, the development of TNX-801, and the promising advancements in their CNS and immunology portfolios underscore their potential to make a lasting impact on global health.  As Tonix continues to innovate and expand its portfolio, it remains poised to address both current and future medical challenges, contributing to a healthier and more resilient world. 7 reasons why Tonix Pharmaceuticals (Nasdaq: TNXP) needs to be  on your watchlist… 1. Urgent Global Health Focus: With the World Health Organization declaring MPX a global health emergency due to a severe strain in Africa, Tonix Pharmaceuticals (Nasdaq: TNXP) is at the forefront of developing critical vax solutions. This urgency places the company in a significant position within the healthcare sector. 2. Limited Float: Tonix Pharmaceuticals (Nasdaq: TNXP) has fewer than 23 Mln shares available in its float, which suggests the potential for significant movements could occur if demand increases. This makes the company one to watch closely in the near term. 3. Potential Technical Reversal: The company’s technical indicators, with RSI levels pointing towards a severely oversold state, suggest a potential trend reversal. This signals that Tonix Pharmaceuticals (Nasdaq: TNXP) could be nearing a pivotal point, making it one company to keep a very close eye on. 4. Cutting-Edge Vax Development: Tonix Pharmaceuticals (Nasdaq: TNXP) is actively developing TNX-801, a vax candidate aimed at combating the rising global health concern of MPX. This effort is rooted in the proven science of Edward Jenner’s small-px vax , which successfully eradicated small-px and is now being adapted to address modern challenges. 5. Innovative Immunology Portfolio: The company is advancing in the field of immunology with products like TNX-1500, a humanized monoclonal antibody targeting CD40-ligand, which is under development for preventing organ transplant rejection and treating autoimmune diseases. This highlights Tonix’s focus on addressing complex medical conditions. 6. Strong Government Partnerships: Tonix Pharmaceuticals (Nasdaq: TNXP)’s recent $34M contract with the U.S. Department of Defense underscores the company's strategic role in enhancing medical readiness against biological threats. This partnership reflects confidence in Tonix's capabilities and its potential to address critical global challenges. 7. Focus on Central Nervous System Disorders: Tonix Pharmaceuticals (Nasdaq: TNXP) is progressing in the treatment of CNS disorders, with TNX-102 SL, a product candidate for fibromyalgia management, expected to be submitted for FDA approval. The company’s work in this area has already achieved significant milestones, including FDA Fast Track designation. Tonix Pharmaceuticals (Nasdaq: TNXP) is at the forefront of addressing some of the most critical global health challenges with its innovative vax developments, strong immunology portfolio, and strategic government partnerships. With a smaller float and technical indicators pointing to a potential reversal, the company is on the brink of significant developments.  From combating MPX to advancing treatments for CNS disorders and contributing to pandemic preparedness, Tonix Pharmaceuticals (Nasdaq: TNXP)’s diverse portfolio positions it as a major player in the healthcare sector.  This makes now the perfect time to start your research and discover the potential of Tonix Pharmaceuticals (Nasdaq: TNXP). Pull up Tonix Pharmaceuticals (Nasdaq: TNXP) right now and start your research. I’ll check in with you shortly. Sincerely, Gary Silver Managing Editor, MarketCrux MarketCrux (MarketCrux . com) is owned by Headline Media LLC, a limited liability company. Disclosure: I am not a lice.nsed finan.cial adviser. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. MarketCrux full disclosure is to be read and fully understood before using MarketCrux website, or joining MarketCrux's email or text list. By viewing MarketCrux website and/or reading MarketCrux email or text newsletter you are agreeing to MarketCrux full disclosure which can be read at marketcrux.com/disclaimer  Pursuant to an agreement between Headline Media LLC and TD Media LLC, Headline Media LLC has been hired for a period beginning on 08/25/2024 and ending on 08/27/2024 to publicly disseminate information about (TNXP:US) via digital communications. Headline Media LLC has been paid seven thousand USD and owns zero shares of (TNXP:US). Please see important additional disclosure information here: https://marketcrux.com/tnxp-disclosure-7894/

Headline Media | 7901 4th Street N Suite 300 | St. Petersburg, FL 33702 US Unsubscribe | Update Profile | Constant Contact Data Notice